Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma

Significant indirect healthcare costs are related to uncontrolled asthma, including productivity loss. Days with short-acting beta-agonist (SABA) use is associated with symptom-related disruptions at work, home, and school. Digital self-management platforms may support fewer days with SABA medicatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaye, Leanne, Vuong, Vy, Barrett, Meredith A., Boers, Elroy, Guilbert, Theresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438376/
https://www.ncbi.nlm.nih.gov/pubmed/36056022
http://dx.doi.org/10.1038/s41533-022-00299-3
_version_ 1784781814911467520
author Kaye, Leanne
Vuong, Vy
Barrett, Meredith A.
Boers, Elroy
Guilbert, Theresa
author_facet Kaye, Leanne
Vuong, Vy
Barrett, Meredith A.
Boers, Elroy
Guilbert, Theresa
author_sort Kaye, Leanne
collection PubMed
description Significant indirect healthcare costs are related to uncontrolled asthma, including productivity loss. Days with short-acting beta-agonist (SABA) use is associated with symptom-related disruptions at work, home, and school. Digital self-management platforms may support fewer days with SABA medication use and may reduce symptom-related disruptions.
format Online
Article
Text
id pubmed-9438376
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-94383762022-09-02 Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma Kaye, Leanne Vuong, Vy Barrett, Meredith A. Boers, Elroy Guilbert, Theresa NPJ Prim Care Respir Med Article Significant indirect healthcare costs are related to uncontrolled asthma, including productivity loss. Days with short-acting beta-agonist (SABA) use is associated with symptom-related disruptions at work, home, and school. Digital self-management platforms may support fewer days with SABA medication use and may reduce symptom-related disruptions. Nature Publishing Group UK 2022-09-02 /pmc/articles/PMC9438376/ /pubmed/36056022 http://dx.doi.org/10.1038/s41533-022-00299-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Kaye, Leanne
Vuong, Vy
Barrett, Meredith A.
Boers, Elroy
Guilbert, Theresa
Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma
title Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma
title_full Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma
title_fullStr Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma
title_full_unstemmed Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma
title_short Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma
title_sort improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438376/
https://www.ncbi.nlm.nih.gov/pubmed/36056022
http://dx.doi.org/10.1038/s41533-022-00299-3
work_keys_str_mv AT kayeleanne improvementinsymptomrelateddisruptionsisassociatedwithfewerdaysofshortactingbetaagonistuseinasthma
AT vuongvy improvementinsymptomrelateddisruptionsisassociatedwithfewerdaysofshortactingbetaagonistuseinasthma
AT barrettmereditha improvementinsymptomrelateddisruptionsisassociatedwithfewerdaysofshortactingbetaagonistuseinasthma
AT boerselroy improvementinsymptomrelateddisruptionsisassociatedwithfewerdaysofshortactingbetaagonistuseinasthma
AT guilberttheresa improvementinsymptomrelateddisruptionsisassociatedwithfewerdaysofshortactingbetaagonistuseinasthma

Ejemplares similares